Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Effect of T Helper (Th)/T Cytotoxic (Tc) Ratio on Disease Severity in Type a Hemophilia Patients Publisher Pubmed



Khazaei HA1 ; Naderi M2 ; Aliabad GM3 ; Tabatabaei SMN1 ; Alidadi A1 ; Moulaei NA4 ; Safdari M1 ; Nahvi H5 ; Cohan N6 ; Dehghan J7 ; Mehraban A8 ; Jalili A9 ; Khazaei A1 ; Khazaei E1 Show All Authors
Authors
  1. Khazaei HA1
  2. Naderi M2
  3. Aliabad GM3
  4. Tabatabaei SMN1
  5. Alidadi A1
  6. Moulaei NA4
  7. Safdari M1
  8. Nahvi H5
  9. Cohan N6
  10. Dehghan J7
  11. Mehraban A8
  12. Jalili A9
  13. Khazaei A1
  14. Khazaei E1
  15. Khazaei B1
  16. Khazaei B1
  17. Rezaei N10
  18. Salarzaie M11
  19. Soleimani G3

Source: Human Antibodies Published:2021


Abstract

BACKGROUND AND OBJECTIVES: The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity. MATERIAL AND METHOD: Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method. RESULTS: Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019. CONCLUSION: The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender. © 2021 - IOS Press. All rights reserved.
Related Docs
View other Related Docs
1. Phylogenetic Analysis and Frequency Estimation of Htlv-1 Virus in Hemophilic Patients Refer to Iranian Comprehensive Hemophilia Care Center (Ichcc), Molecular Genetics# Microbiology and Virology (2023)
2. Discrepancy Between the Results of One-Stage and Chromogenic Factor Viii:C Assays in Patients With Mild/Moderate Hemophilia A, Blood Coagulation and Fibrinolysis (2020)
3. Health Status and Quality of Life in Patients With Severe Hemophilia A: A Cross-Sectional Survey, Hematology Reports (2019)
Experts (# of related papers)
View all Related Experts
Gholamreza Toogeh (3)
Majid Davari (2)
Other Related Docs
4. Hla-Drb1*01:01, But Not Hla-Drb1:1503 or Hla-Drb1*11, Is Associated With Decreased Inhibitor Risk in Iranian Hemophilia a Patients, Transfusion and Apheresis Science (2019)
5. Health Care Resource Utilization and Cost of Care for Haemophilia a and B Patients in Iran, Transfusion and Apheresis Science (2016)
6. Bleeding Disorder of Unknown Cause: Results From Iranian Study, Transfusion and Apheresis Science (2023)
7. Acquired Hemophilia a With Intramuscular Hematoma at an Unusual Age: A Case Report, Russian Journal of Pediatric Hematology and Oncology (2022)
8. Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor Ii and Factor V With Risk of Inhibitor Development in Patients With Severe Hemophilia A, Cardiovascular and Hematological Disorders - Drug Targets (2019)
9. Establishing Normal Ranges of Hematological Parameters From an Iranian Healthy Population: A Population-Based Cross-Sectional Study of Hospital Data, Acta Medica Iranica (2018)
10. Unbalanced T-Cell Subsets in Pediatric Patients With Beta-Thalassemia, Human Immunology (2023)
11. Seroprevalence of Toxocariasis Among Hypereosinophilic Children: A Single Center Study, Tehran, Iran, Archives of Pediatric Infectious Diseases (2023)
12. Genetic Analysis of Non-Severe Hemophilia a Phenotype With a Discrepancy Between One-Stage and Chromogenic Factor Viii Activity Assays, Transfusion and Apheresis Science (2021)
13. The Frequency of Hla-Dq2/Dq8 Haplotypes and Celiac Disease Among the First-Degree Relatives of Patients With Celiac Disease, Gastroenterology and Hepatology from Bed to Bench (2021)
14. Key Data Elements to Design Self-Care Mobile-Based Application for Hemophilia, Frontiers in Health Informatics (2024)
15. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
16. Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group, International Journal of Hematology-Oncology and Stem Cell Research (2021)